Latest Omalizumab Stories
- 90% of subjects had reduction of free IgE to below the limit of detection by the end of XmAb7195 infusion, including at lowest dose evaluated of 0.3 mg/kg - MONROVIA, Calif.,
TSX Venture: QPT EDMONTON, Jan. 13, 2015 /PRNewswire/ - Quest PharmaTech Inc.
The Firm is evaluating legal claims on behalf of individuals who allegedly suffered serious Xolair side effects, including heart attacks, mini-strokes, pulmonary hypertension, and blood clots
-- Today is the first ever International Urticaria Day, an international event to increase urticaria awareness and improve care around the globe and let people living with urticaria
On September 26, the FDA issued a safety communication on potential risks of cardiovascular and cerebrovascular serious adverse events to Xolair's (omalizumab) drug label.
Efficacy on Reducing Exacerbations and Hospitalizations is One of the Key Drug Attributes for Formulary Inclusion, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug.
Conference call today at 4:30 p.m. EDT MONROVIA, Calif., July 31, 2014 /PRNewswire/ -- Xencor Inc.
While Expressing Concerns about Reimbursement, EU5 Payers Look Favorably on Identifying Anti-IL5 Therapy-Responsive Patients, According to Findings from Decision Resources Group BURLINGTON,
MONROVIA, Calif., May 28, 2014 /PRNewswire/ -- Xencor, Inc.
Rapid IgE clearance by XmAb7195 shows potential as a disease modifying treatment for allergy and asthma MONROVIA, Calif., May 15, 2014 /PRNewswire/ -- Xencor, Inc.